AXIM Biotech Advances Multiple Sclerosis Program --

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
181
AXIM Biotech Advances Multiple Sclerosis Program -- SECFilings.com

REDONDO BEACH, CA--(Marketwired - May 4, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering how AXIM® Biotechnologies Inc.'s ( OTC PINK : AXIM ) MedChew Rx® could become a treatment option for patients suffering from multiple sclerosis -- or M.S. -- and the company's progress in beginning clinical trials.

Multiple Sclerosis

Multiple sclerosis is a debilitating disease whereby the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage impedes communication throughout the nervous system, which results in physical, mental, and psychiatric problems.

There is no known cure for multiple sclerosis, but there are treatments that improve function after an attack and prevent new attacks. According to GlobalData, the market for these treatments is expected to reach $20 billion by 2024, driven by the continued development of new products and an increase in diagnoses around the world. There were roughly 2.3 million people diagnosed with the disease around the world in 2015.

Cannabinoid Solutions

Cannabinoids have shown promise in treating the symptoms of multiple sclerosis in clinical trials. For instance, GW Pharmaceuticals plc developed Sativex as an under-the-tongue spray designed to alleviate these symptoms with both THC and CBD. The company received regulatory approval in 16 countries outside of the United States for the treatment of pain and spasticity associated with multiple sclerosis.

In randomized controlled trials , Sativex was shown to significantly reduce neuropathic pain, spasticity, muscle spasms, and sleep disturbances. The most common adverse effects reported were dizziness, sleepiness, fatigue, feeling of intoxication, and bad taste. While the long-term safety of the treatment is classified as "unknown", cannabinoids have been used for hundreds of years without significant acute side effects in most populations.

AXIM Biotech is developing its MedChew Rx pharmaceutical chewing gum as a treatment for pain and spasticity associated with multiple sclerosis. The company plans to leverage the same benefits of cannabinoids while improving the delivery system used. Its chewing gum based delivery system may enhance bioavailability and give patients a better tasting and more convenient method of delivery than a sublingual spray, pill, or other options.

Clinical Development

AXIM Biotech recently announced that its product development partner, Quay Pharmaceuticals Ltd., has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of MedChew Rx products.

"It is a very exciting development process we have embarked on with AXIM and we are delighted to be supporting them on their range of projects," said Quay Pharma CEO Maireadh Pedersen. "The development of the MedChew Rx gum will be carefully formulated to ensure that the drugs are preferentially absorbed orally within a specific window of time to provide the best therapeutic outcome for patients."

The company procures cannabis strains from the Dutch government's Office of Medicinal Cannabis, which provides it with a low-cost source of high-quality pharmaceutical-grade base materials grown by Bedrocan BV -- the world's only GMP-certified facility for pharmaceutical grade cannabis. In partnership with Syncom BV, the company takes this base material and processes it into 99.9% pure pharmaceutical-grade cannabinoids.

Please follow the link to read the full article: http://analysis.secfilings.com/articles/169-a...is-program

About SECFilings.com

Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx .

SECFilings.com Paul Archie 406-862-2242 parchie@secfilings.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 31

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Ajman Media Forum Puts Trust Ahead of AI Speed in 2026

Updated Category News Views 179

Algorithms may manufacture a flood of words, but they cannot inherit accountability. That was the sensible nerve running through Ajman Media Forum 2026, “The Signal,” inaugurated on November 19 by His Highness Sheikh Ammar bin Humaid Al Nuaimi, Crown Prince of Ajman and Chairman of the Executive Council. For all the fanfare that usually surrounds artificial...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 75

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 86

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 73

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 5

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 46

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 111

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
McDonald's Franchise Wage Suit Puts Compliance on Notice

Updated Category News Views 129

Payroll sloppiness can turn a cheap burger shift into an expensive courtroom problem fast. Zakay Law Group, APLC has filed a proposed class action in Alameda County Superior Court against a long list of McDonald's franchise-related entities, alleging workers were not paid all wages due under California law. The case, 26CV218760, is pending, not proven, and that...

Continue Reading

Top 5 Most Recently Viewed Articles

PI Strengthens U.S. Manufacturing with New Facility Opening

Updated Category News Views 277

PI Enhances U.S. Manufacturing Capabilities PI (Physik Instrumente) is making significant strides in its operations by expanding its manufacturing capabilities in the United States. This move, aimed at strengthening its customer support, comes as the company prepares to open a new production facility soon. The expansion is a strategic response to current trade challenges...

Continue Reading
Revolutionizing K-12 Education with RightFind Curriculum

Updated Category News Views 157

Introducing the RightFind Curriculum by CCC CCC, a leader in copyright innovation, has launched its newest solution: the RightFind Curriculum. This tool is designed to help integrate high-quality, copyrighted materials into K-12 educational settings. It specifically caters to educators, EdTech companies, and curriculum developers, making it easier to search for and use...

Continue Reading
Essential Tips for Homebuyers During Peak Season

Updated Category News Views 157

Essential Tips for Homebuyers During Peak Season Spring is often seen as the height of the homebuying season. Many buyers aim to purchase homes and settle in before the summer months, especially before the new school year approaches. To assist homebuyers in navigating this critical time, the Pennsylvania Association of Realtors has shared useful insights. The Importance...

Continue Reading
Wolfspeed Faces Securities Fraud Lawsuit: What Investors Should Know

Updated Category News Views 926

Wolfspeed, Inc. Under Securities Fraud Investigation As many investors navigate turmoil in the stock market, a recent development concerning Wolfspeed, Inc. is drawing significant attention. Block & Leviton has announced that a lawsuit for securities fraud has been filed against Wolfspeed, Inc. (WOLF) and several of its executives. For those who have experienced financial...

Continue Reading
Ero Copper Corp. Set to Announce Q3 Results This November

Updated Category News Views 210

Ero Copper Corp. Prepares for Q3 Financial Results Release VANCOUVER, British Columbia – Excitement is building for Ero Copper Corp. (TSX: ERO, NYSE: ERO) as the company is set to publish its operating and financial results for the third quarter of 2025 on November 4. This announcement will occur after the market closes, providing valuable insights into the company’s...

Continue Reading